CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2013--
Agios Pharmaceuticals, Inc. today announced the closing of its initial
public offering of 6,772,221 shares of its common stock at a public
offering price of $18.00 per share, before underwriting discounts,
including 883,333 shares of common stock issued upon the exercise in
full by the underwriters of their option to purchase additional shares
at the public offering price, less the underwriting discount.
J.P. Morgan and Goldman, Sachs & Co. acted as joint book-running
managers for the offering. Cowen and Company and Leerink Swan acted as
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 23, 2013.
Copies of the final prospectus related to this offering may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, telephone:
866-803-9204; or Goldman, Sachs, & Co. Attn: Prospectus Department, 200
West Street, New York, NY 10282, telephone: 866-471-2526, facsimile:
212-902-9316, e-mail: email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company passionately
committed to applying its scientific leadership in the field of cellular
metabolism to transform the lives of patients with cancer and inborn
errors of metabolism, or IEMs, which are a subset of orphan genetic
Source: Agios Pharmaceuticals, Inc.
for Agios Pharmaceuticals, Inc.